Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 5/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.35 |
| ▸ | STK25 | O00506 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16675932 | 0.87 | EGFR (0.42) | EGFRCNR2CHRNA3LCKRET | |
| SCHEMBL16682131 | 0.86 | WDR5 (0.37) | EGFRCNR2CHRNA3WDR5POLB | |
| SCHEMBL16682118 | 0.83 | MAPK1 (0.42) | EGFRCNR2CHRNA3WDR5RET | |
| SCHEMBL16682178 | 0.83 | CNR2 (0.40) | CNR2WDR5LCKRETSRC | |
| SCHEMBL16682108 | 0.81 | CYP2D6 (0.44) | WDR5POLBL3MBTL1HIF1AEPAS1 | |
| SCHEMBL16682115 | 0.80 | CRHR1 (0.36) | CNR2LCKRETSRCCACNA1I | |
| SCHEMBL16682128 | 0.79 | RET (0.39) | LCKRETSRCSTK25 | |
| SCHEMBL16682130 | 0.77 | STK25 (0.39) | LCKRETSRCCACNA1ISTK25 | |
| SCHEMBL16682113 | 0.77 | CRHR1 (0.38) | CNR2POLBLCKRETSRC | |
| SCHEMBL16682184 | 0.74 | STK25 (0.39) | CNR2LCKRETSRCCACNA1I |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580391-B2 | Saturated acyl guanidine for inhibition of F1F0-ATPase | LYCERA CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119439-A1 | SATURATED ACYL GUANIDINE FOR INHIBITION OF F1F0-ATPASE | ATP5F1A, ATP5F1D, ATP5F1C | EGFR 4181/4885CNR2 4204/4885CHRNA3 4412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.